Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  232.52
+0.14 (0.06%)
AAPL  273.40
-0.41 (-0.15%)
AMD  214.99
-0.05 (-0.02%)
BAC  56.17
-0.08 (-0.14%)
GOOG  314.96
-0.71 (-0.22%)
META  663.29
-4.26 (-0.64%)
MSFT  487.71
-0.31 (-0.06%)
NVDA  190.53
+1.92 (1.02%)
ORCL  197.99
+0.50 (0.25%)
TSLA  475.19
-10.21 (-2.10%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.